The company's proprietary extended-release drug delivery technology platform allows it to develop extended-release ODT or extended-release oral suspension formulations of existing extended-release medications.

Its growing ADHD product portfolio puts Neos in a unique position to help meet the different needs of patients that struggle with the condition.